Deal title Principal company/nonprofit Partner company/nonprofit Value (US$M) Start date
EMD Serono and ACP to conduct clinical trial on comparison of evobrutinib with interferon beta-1a for multiple sclerosis Accelerated Cure Project EMD Serono Inc. Payment unspecified 9/10/19
St George Street Capital and Astrazeneca to develop two new compounds for idiopathic male infertility and renal transplant rejection Astrazeneca plc St George Street Capital Payment unspecified 9/24/19
ML Bio Solutions and Atrium Health to develop BBP-418 for LGMD2i Atrium Health ML Bio Solutions Payment unspecified 9/5/19
CIBMTR to collect and analyze retrospective and prospective data of phase III study of Gamida's omidubicel for hematologic malignancies Center for International Blood and Marrow Transplant Research Gamida Cell Ltd. Payment unspecified 9/11/19
Chattanooga Center for Neurologic Research to conduct research on CTD's Trappsol Cyclo for Alzheimer's disease Chattanooga Center for Neurologic Research CTD Holdings Inc. Payment unspecified 9/27/19
RFTCA to use Chromocell's Chromovert Technology to research, develop and commercialize a cure for HIV/AIDS Chromocell Corp. Research Foundation to Cure AIDS Payment unspecified 9/4/19
Tonix Pharmaceuticals to develop Columbia University's TNX-1700 for gastric and pancreatic cancers Columbia University Tonix Pharmaceuticals Holding Corp. Payment unspecified 9/16/19
Gene Techno Science and Gifu Pharmaceutical to develop therapeutic treatments for an ophthalmologic disease using human exfoliated deciduous teeth Gifu Pharmaceutical University Gene Techno Science Co. Ltd. Payment unspecified 9/18/19
Kaleido and Gustave Roussy to identify and characterize microbiome metabolic therapies to improve cancer immunotherapy efficacy Gustave Roussy Kaleido Biosciences Inc. Payment unspecified 9/9/19
Guy's & St Thomas to conduct phase II clinical trials of Evgen Pharma's SFX-01 against autism Guy's & St Thomas' Hospital NHS Trust Evgen Pharma plc Payment unspecified 9/5/19
Moderna and Harvard University to develop mRNA nanoparticle delivery technology for immunological diseases Harvard University Moderna Therapeutics $2.45 9/26/19
Valo Therapeutics licensed from Helsinki University access to Peptienv technology that enables the coating of enveloped viruses by neoantigen-peptides Helsinki University Valo Therapeutics Ltd. Payment unspecified 9/4/19
Exosome Sciences and presumably Hoag Memorial Hospital Presbyterian to identify exosome markers for cancer diagnosis Hoag Memorial Hospital Presbyterian Exosome Sciences Payment unspecified 9/23/19
Jain Foundation to conduct Catabasis' preclinical research of edasalonexent against dysferlinopathy Jain Foundation Catabasis Pharmaceuticals Inc. Payment unspecified 9/26/19
Jefferson Health to evaluate Context Therapeutics' Apristor combination therapy in advanced endometrial cancer Jefferson Health Context Therapeutics LLC Payment unspecified 9/19/19
DCB and Kaohsiung Medical University to enter memorandum of understanding for the development of new drugs Kaohsiung Medical University Development Center for Biotechnology Payment unspecified 9/12/19
Massachusetts General Hospital to conduct platform trial for Biohaven’s verdiperstat for amyotrophic lateral sclerosis Massachusetts General Hospital Biohaven Pharmaceutical Holding Co. Ltd. Payment unspecified 9/18/19
Irbm and MD Anderson to develop monoclonal antibodies against immune checkpoint target MD Anderson Cancer Center Irbm SpA Payment unspecified 9/16/19
EA Pharma to develop and commercialize NCNP's OCH-NCNP1 for multiple sclerosis and Crohn’s disease worldwide National Center Of Neurology & Psychiatry EA Pharma Co. Ltd. Payment unspecified 9/6/19
Celsius Therapeutics and Parker Institute to research on molecular mechanisms and targets for immune checkpoint inhibitor therapies in cancers Parker Institute for Cancer Immunotherapy Celsius Therapeutics Inc. Payment unspecified 9/19/19
Three Lakes Partners and PFF to develop therapies and cures for lung disease Pulmonary Fibrosis Foundation Three Lakes Partners LLC Payment unspecified 9/4/19
Astellas to develop and commercialize cell therapy using Riken's artificial adjuvant vector cell technology for cancer worldwide Riken Astellas Pharma Inc. $9.09 9/2/19
Samsung Bioepis and Ministry of Health to market Brenzys in Brazil Samsung Bioepis Co. Ltd. Brazil's Ministry of Health Payment unspecified 9/16/19
Gene Techno and Showa University School of Medicine to develop new therapeutic treatments for bone-related diseases Showa University Gene Techno Science Co. Ltd. Payment unspecified 9/10/19
Solti to conduct clinical research on Context Therapeutics' Apristor in breast cancer patients Solti Breast Cancer Research Group Context Therapeutics LLC Payment unspecified 9/16/19
Stanford University and Allogene Therapeutics to test charge-altering releasable transporter system for delivering nucleic acids into lymphocytes, including T cells Stanford University Allogene Therapeutics Inc. Payment unspecified 9/19/19
Vesselon to use Temple University's patented technology to enable the viral therapy for repeated delivery of systemic injection worldwide Temple University Vesselon Inc. Payment unspecified 9/17/19
Myokardia and Cleveland Clinic Research to evaluate Mavacamten as alternative to septal reduction therapy in obstructive hypertrophic cardiomyopathy The Cleveland Clinic Research Institute Myokardia Inc. Payment unspecified 9/10/19
Ivy Brain Tumor Center and QED Therapeutics to investigate infigratinib to treat glioblastoma The Ivy Brain Tumor Center QED Therapeutics Inc. Payment unspecified 9/24/19
Silverstein Foundation and Q-State Biosciences to form Chamishi Therapeutics for developing antisense oligonucleotide therapies for Glucosylceramidase beta acid-Parkinson's disease The Silverstein Foundation Q-State Biosciences Inc. Payment unspecified 9/26/19
HHS exercised its option to purchase an additional 10,000 doses of Biocryst's Rapivab U.S. Department of Health and Human Services Biocryst Pharmaceuticals Inc. Payment unspecified 9/26/19
Dcprime and UMCG to develop DCP-001 for ovarian cancer University Medical Center Groningen Dcprime BV Payment unspecified 9/10/19
Debut to use University of California Irvine's technology for continuous manufacture of pharmaceuticals and cannabinoids University of California Irvine Debut Biotechnology Payment unspecified 9/18/19
Avicanna and the University of Guelph to develop prescription and OTC cannabinoid products for psychiatric disorders University of Guelph Avicanna Inc. Payment unspecified 9/13/19
Valo Therapeutics to use Helsinki University's Peptienv technology to develop therapeutics against cancer University of Helsinki Valo Therapeutics Ltd. Payment unspecified 9/2/19
Spherix to use University of Kentucky's patent rights related to G4-1 to treat cancer University of Kentucky Spherix Inc. Payment unspecified 9/11/19
Spherix to acquire an option for University of Maryland's anthrax based PrAg-PAS to treat ovarian cancer University of Maryland Spherix Inc. Payment unspecified 9/17/19
University of Melbourne to spin out Denteric to develop and commercialize the research outputs, including a vaccine for periodontal gum disease University of Melbourne Denteric Pty Ltd. Payment unspecified 9/26/19
University of Oxford to develop Crescendo Biologics' CB-307 for prostate-specific membrane antigen positive tumor University of Oxford Crescendo Biologics Ltd. Payment unspecified 9/12/19
Destiny Pharma and University of Sheffield to investigate XF compounds including, DPD-207 and XF-73 targeting ophthalmic bacterial and fungal infections University of Sheffield Destiny Pharma Ltd. Payment unspecified 9/10/19
Iq Group Global acquires University of Texas' TEX-Core to treat cancer therapeutics University of Texas System The Iq Group Global Payment unspecified 9/16/19
Batavia to develop VUMC's ZIKV-117 using GS knockout CHO K1 cell line expression system against Zika virus infection Vanderbilt University Medical Center Batavia Biosciences BV Payment unspecified 9/3/19
Viriom and NIH to develop elsulfavirine for HIV infection Viriom Inc. National Institutes of Health Payment unspecified 9/3/19
IMV and Wistar Institute to develop a targeted T-cell therapy against BRAF cancer mutation Wistar Institute of Anatomy & Biology IMV Inc. Payment unspecified 9/4/19

No Comments